Validation of Prediction Models for Near Adult Height in Children with Idiopathic Growth Hormone Deficiency Treated with Growth Hormone: A Belgian Registry Study

Straetemans, Saartje; Schepper, Jean De; Thomas, Muriel; Verlinde, Franciska; Rooman, Raoul

doi:10.1159/000448553

Cited by 12 publications

(10 citation statements)

References 23 publications

(36 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, although the treatment response to MPHD is better, FAH-SDS can be similar to that seen in patients with IGHD (GHD) due to more severe GHD, shorter initial height, and the presence of other hormone deficiencies accompanying GHD ( 22 ). In agreement with previous reports, both delta height SDS and FAH-SDS were higher in patients with MPHD than patients with IGHD ( 6 , 14 , 15 , 16 , 18 ). This was attributed to younger age for the onset of the treatment, longer duration of treatment, lower bone age, and lower IGF1 SDS as well as peak GH values in the GH stimulation test.…”

Section: Discussionsupporting

confidence: 93%

“…In an international study in 1619 patients with IGHD the FAH-SDS was reported to be -1.4 SD ( 6 ). Cappa et al ( 16 ), Rachmiel et al ( 17 ), Straetemans et al ( 18 ), Carel et al ( 19 ), and Thomas et al ( 20 ) reported -0.86, -1.04, -1.74, -1.6, -0.8 FAH-SDS in patients with IGHD, respectively. In all these studies, although the GH treatment dose was similar or lower than our study in IGHD groups, FAH-SDS were better than in our study, and delta height SDS was similar ( Table 4 ).…”

Section: Discussionmentioning

confidence: 97%

“…In our study, mean MPH-SDS was -1.3, which was achieved in 80% of the patients diagnosed with IGHD. In studies evaluating the GH treatment response, the mean FAH-MPH has been reported to be between 0.0 and -0.6 SD ( 6 , 14 , 15 , 16 , 17 , 18 , 19 , 20 ). In our study, FAH-MPH-SDS was -0.43 SD in IGHD and -0.15 SD in MPHD, and the findings were consistent with the literature.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Evaluation of the Final Adult Height and Its Determinants in Patients with Growth Hormone Deficiency: A Single-centre Experience from the South-Eastern Region of Turkey

Demiral¹,

Ünal²,

Baysal³

et al. 2020

Jcrpe

View full text Add to dashboard Cite

The aim was to determine the final adult height (FAH) achieved by recombinant human growth hormone (rhGH) treatment, the factors affecting FAH and the success of attaining the genetic potential. Methods: Data of 133 patients treated with rhGH therapy were reviewed retrospectively. Patients were grouped according to diagnosis, either isolated GH deficiency (IGHD) or multiple pituitary hormone deficiency (MPHD), and by sex, and pubertal status at the beginning of treatment. Results: The mean age of initiation of treatment was 12.3±2.18 years, and the mean duration of rhGH treatment was 3.65±1.5 years. The mean height standard deviation score (SDS) at diagnosis was-3.11±0.75 SD. All patients received a standardized GH dose of 0.033 mg/kg/day. Mean FAH-SDS was-1.8±0.77 and delta height-SDS (the change in height SDS between the beginning and end of treatment) was 1.28±0.94 SD. FAH-SDS was-1.79±0.86 SD in males;-1.82±0.64 in females (p=0.857);-1.94±0.71 at the beginning of treatment in pubertal patients and-1.68±0.81 in prepubertal patients (p=0.056);-1.84±0.89 in patients with IGHD and-0.47±0.2 in patients with MPHD (p˃0.05). In multiple regression analysis, First year delta height-SDS was the most predictive factor for both FAH-SDS and delta height-SDS. Conclusion: The majority of our patients achieved a final height compatible with their genetic potential as well as population standards when treated with rhGH even having started at a relatively late age. First year delta height-SDS was a predictive factor for FAH.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of the Final Adult Height and Its Determinants in Patients with Growth Hormone Deficiency: A Single-centre Experience from the South-Eastern Region of Turkey

Demiral¹,

Ünal²,

Baysal³

et al. 2020

Jcrpe

View full text Add to dashboard Cite

show abstract

“…The response to GH therapy in children has been traditionally expressed in terms of growth velocity (GV) measured as cm/year. In our cohort of patients, after one year of treatment, the average GV was 9.4 ± 3.5 cm, similar to that reported in larger studies [22,36]. The difference between near-adult height SDS and mid-parental target height SDS is, however, considered as the best indicator of whether an individual has achieved his/her height potential [10].…”

Section: δIgf-1 Z-supporting

confidence: 88%

Correlation Between the Responses to Growth Hormone (GH) Treatment During Childhood and Adulthood in a Monocentric Cohort of GH-Deficient Patients

et al. 2018

View full text Add to dashboard Cite

Our aim was to analyze a cohort of patients with childhood-onset growth hormone deficiency (GHD) to evaluate if there is some correlation between the response to GH treatment during childhood and adulthood, respectively. This was an observational retrospective monocentric cohort study of 47 patients treated with GH during childhood and adulthood. Changes in growth parameters during childhood were compared with the increase of IGF-I z-score and other indexes of GH response (body composition, lipid profile) after 1 year of treatment in adulthood. The only significant positive correlation was observed between final growth velocity during the last year of childhood GH treatment and increase in IGF-I z-score in GH-treated adults (r=0.592, p=< 0.01). No correlation was observed between growth-promoting effects of GH as child and metabolic changes induced by GH as adult. We also observed a negative correlation between weight at the end of childhood GH treatment and the IGF-I response during first year of treatment in adults (r=- 0.335, p <0.05). No significant positive correlation could be observed between the main parameters that evaluate response to GH treatment in children and adults. However, the final growth velocity, which may be considered as one of the main criteria of end of GH treatment in children, was identified as parameter that could predict future response to GH treatment in adulthood.

show abstract

“…However, the predicted FAH following a short period of treatment is dynamic and cannot reflect the actual FAH. Owing to the heterogeneity of the treated ISS populations and the individualization of treatment, only a few randomized trials with small sample sizes have observed ISS until FAH [6][7][8][9][10]. A randomized study of FAH typically takes 8 years or more to complete and is often difficult to implement in clinical settings.…”

Section: Introductionmentioning

confidence: 99%

Final adult height of children with idiopathic short stature: a multicenter study on GH therapy alone started during peri-puberty

Chen

et al. 2020

BMC Pediatr

View full text Add to dashboard Cite

Background: To evaluate the efficacy of GH in improving FAH in ISS children in a multicenter study. Methods: A real-world observation was carried out. Children with ISS in seven hospitals in China were enrolled. The height gains standard deviation score and the height gain over the target height were evaluated. Results: There were 344 ISS patients (217 boys and 127 girls). The baseline average age of boys and girls was 12.7 and 11.7 years, with bone age of 11.7 and 10.1 years, respectively. The baseline height SDS of boys and girls was − 3.07 and − 2.74, and the FAH SDS was − 1.91 and − 1.38, respectively. Compared with the baseline height SDS, the FAH SDS was significantly increased in both boys and girls (both P = 0.0000). The FAH SDS was the highest (gain by 1.54 SD) in the ≥2y treatment course group. Two hundred eighteen patients (218/344, 63.4%) had a FAH SDS > − 2 SD. Among these patients, girls in the 1-2y treatment course group and ≥ 2y group had a FAH SDS higher than TH SDS. Even in the control group, a spontaneous catch-up growth of 1.16 SD was observed. A multivariate linear regression model was used to analyze the results, with FAH SDS as the dependent variable. It was found that the treatment course and baseline height SDS in the boys' model were statistically significant (P < 0.05), whereas the baseline height SDS and baseline bone age significantly affected the girls' FAH SDS (P < 0.05). Conclusions: Both girls and boys of ISS improved FAH by GH therapy even if treatments begin over 10 years old and majority of them reached TH. Some peri-puberty ISS will have a spontaneous height gain. We recommend the course of GH treatment more than 2 years for girls, and longer courses for boys.

show abstract

Validation of Prediction Models for Near Adult Height in Children with Idiopathic Growth Hormone Deficiency Treated with Growth Hormone: A Belgian Registry Study

Cited by 12 publications

References 23 publications

Evaluation of the Final Adult Height and Its Determinants in Patients with Growth Hormone Deficiency: A Single-centre Experience from the South-Eastern Region of Turkey

Evaluation of the Final Adult Height and Its Determinants in Patients with Growth Hormone Deficiency: A Single-centre Experience from the South-Eastern Region of Turkey

Correlation Between the Responses to Growth Hormone (GH) Treatment During Childhood and Adulthood in a Monocentric Cohort of GH-Deficient Patients

Final adult height of children with idiopathic short stature: a multicenter study on GH therapy alone started during peri-puberty

Contact Info

Product

Resources

About